Effectiveness and Safety of a Mixture of Nobiletin and Tangeretin in Nocturia Patients: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study

被引:5
|
作者
Ito, Haruki [1 ]
Negoro, Hiromitsu [2 ]
Kono, Jin [3 ]
Hayata, Naoki [1 ]
Miura, Takayoshi [1 ]
Manabe, Yumi [1 ]
Miyazaki, Yu [1 ]
Mishina, Mutsuki [1 ]
Woo, Je Tae [4 ]
Sakane, Naoki [5 ]
Okuno, Hiroshi [1 ]
机构
[1] Natl Hosp Org, Kyoto Med Ctr, Dept Urol, Kyoto 6128555, Japan
[2] Univ Tsukuba, Inst Med, Dept Urol, Tsukuba 3058575, Japan
[3] Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto 6068507, Japan
[4] Chubu Univ, Coll Biosci & Biotechnol, Dept Biol Chem, Kasugai 4878501, Japan
[5] Natl Hosp Org, Clin Res Inst, Kyoto Med Ctr, Div Prevent Med, Kyoto 6128555, Japan
关键词
clinical trial; flavonoid; voiding diary; URINARY-TRACT SYMPTOMS; NETWORK; MEN;
D O I
10.3390/jcm12082757
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nobiletin and tangeretin (NoT) are flavonoids derived from the peel of Citrus depressa, and they have been found to modulate circadian rhythms. Because nocturia can be considered a circadian rhythm disorder, we investigated the efficacy of NoT for treating nocturia. A randomized, placebo-controlled, double-blind, crossover study was conducted. The trial was registered with the Japan Registry of Clinical Trials (jRCTs051180071). Nocturia patients aged >= 50 years who presented nocturia more than 2 times on a frequency-volume chart were recruited. Participants received NoT or a placebo (50 mg once daily for 6 weeks), followed by a washout period of >= 2 weeks. The placebo and NoT conditions were then switched. Changes in nocturnal bladder capacity (NBC) were the primary endpoint, and changes in nighttime frequency and nocturnal polyuria index (NPi) were secondary endpoints. Forty patients (13 women) with an average age of 73.5 years were recruited for the study. Thirty-six completed the study, while four withdrew. No adverse events directly related to NoT were observed. NoT had little effect on NBC compared with the placebo. In contrast, NoT significantly changed nighttime frequency by -0.5 voids compared with the placebo (p = 0.040). The change in NPi from baseline to the end of NoT was significant (-2.8%, p = 0.048). In conclusion, NoT showed little change in NBC but resulted in decreased nighttime frequency with a tendency toward reduced NPi.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] FELODIPINE IN CHRONIC STABLE ANGINA - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY
    SANGIORGIO, P
    DIPASQUALE, G
    SAVONITTO, S
    URBINATI, S
    RUBBOLI, A
    CAVALLOTTI, G
    PINELLI, G
    BRACCHETTI, D
    EUROPEAN HEART JOURNAL, 1990, 11 (11) : 1011 - 1017
  • [22] Ondansetron in patients with tinnitus: randomized double-blind placebo-controlled study
    Taslimi, Shervin
    Vahidi, Hamed
    Pourvaziri, Ali
    Modabbernia, Amirhossein
    Fallah, Arezoo Yeke
    Yazdani, Nasrin
    Taslimi, Negin
    Hosseini, Mostafa
    Zarandi, Masoud Motesadi
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2013, 270 (05) : 1635 - 1641
  • [23] Ondansetron in patients with tinnitus: randomized double-blind placebo-controlled study
    Shervin Taslimi
    Hamed Vahidi
    Ali Pourvaziri
    Amirhossein Modabbernia
    Arezoo Yeke Fallah
    Nasrin Yazdani
    Negin Taslimi
    Mostafa Hosseini
    Masoud Motesadi Zarandi
    European Archives of Oto-Rhino-Laryngology, 2013, 270 : 1635 - 1641
  • [24] EFFICACY AND SAFETY OF QUETIAPINE FOR DELIRIUM IN ICU PATIENTS:A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Devlin, John W.
    Roberts, Russel
    Fong, Jeffrey J.
    Skrobik, Yoanna
    Harvey, Johanne
    Riker, Richard
    Robbins, Tracey
    Hill, Nicholas
    Garpestad, Erik
    CRITICAL CARE MEDICINE, 2008, 36 (12) : A17 - A17
  • [25] Safety of celecoxib in patients with ulcerative colitis in remission: A randomized, double-blind, placebo-controlled study
    Sandborn, WJ
    Stenson, WF
    Brynskov, J
    Steidle, G
    Robbins, J
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S257 - S258
  • [26] Diclofenac for treatment of nocturia caused by nocturnal polyuria: A prospective, randomised, double-blind, placebo-controlled crossover study
    Addla, SK
    Adeyoju, AB
    Neilson, D
    O'Reilly, P
    EUROPEAN UROLOGY, 2006, 49 (04) : 720 - 726
  • [27] Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men
    Mattiasson, A
    Abrams, P
    Van Kerrebroeck, P
    Walter, S
    Weiss, J
    BJU INTERNATIONAL, 2002, 89 (09) : 855 - 862
  • [28] LOW DOSE DESMOPRESSIN AND TOLTERODINE FOR NOCTURIA IN FEMALE PATIENTS WITH OVERACTIVE BLADDER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Rovner, E.
    Norgaard, J. P.
    Raymond, K.
    Juul, K.
    NEUROUROLOGY AND URODYNAMICS, 2015, 34 : S34 - S35
  • [29] EFFICACY AND SAFETY OF CREATINE SUPPLEMENTATION IN JUVENILE DERMATOMYOSITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER TRIAL
    Solis, Marina Yazigi
    Hayashi, Ana Paula
    Artioli, Guilherme Giannini
    Roschel, Hamilton
    Sapienza, Marcelo Tatit
    Otaduy, Maria Concepcion
    De Sa Pinto, Ana Lucia
    Silva, Clovis Artur
    Elias Sallum, Adriana Maluf
    Pereira, Rosa Maria R.
    Gualano, Bruno
    MUSCLE & NERVE, 2016, 53 (01) : 58 - 66
  • [30] Randomized double-blind, placebo-controlled, crossover study of men with prostate cancer and rising PSA:: Effectiveness of a dietary supplement
    Schröder, FH
    Roobol, MJ
    Boevé, ER
    De Mutsert, R
    Verwillegen, W
    Zuidgeest, S
    Wildhagen, MF
    Van Helvoort, A
    JOURNAL OF UROLOGY, 2004, 171 (04): : 334 - 335